WARPTECHNEWS · LAB

Home AI Business Tech Archive

Storia: Brazil approves generic GLP-1 drug sold by Swiss firm Sandoz — Warptech Lab News

Storia in 4 fonti

Brazil approves generic GLP-1 drug sold by Swiss firm Sandoz

Brazil approves Sandoz-marketed Owozy for type 2 diabetes, with launch planned in late 2026.

Raccontata da

valor.globo.com

thehindubusinessline.com

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

swissinfo.chStai leggendo3 g fa

Brazil approves generic GLP-1 drug sold by Swiss firm Sandoz

Brazil approves Sandoz-marketed Owozy for type 2 diabetes, with launch planned in late 2026.

thehindu.com2 g fa

Sun Pharma gets Brazil nod for Semaglutide

Sun Pharma receives ANVISA approval to launch semaglutide in Brazil, expanding diabetes treatment options in a $413 million market.

Leggi questa versione → originale

Timeline cronologica

mercoledì 29 luglio 2026·valor.globo.com
Em parceria com laboratório Adalvo, Sandoz ingressa no mercado de semaglutida com Owozy
Em parceria com laboratório Adalvo, Sandoz ingressa no mercado de semaglutida com Owozy
mercoledì 29 luglio 2026·swissinfo.ch
Brazil approves generic GLP-1 drug sold by Swiss firm Sandoz
Brazil approves Sandoz-marketed Owozy for type 2 diabetes, with launch planned in late 2026.

thehindubusinessline.com2 g fa

Sun Pharma gets green signal on semaglutide in Brazil, its second export market

Sun Pharma gains ANVISA approval to launch semaglutide in Brazil, partnering with Hypera Pharma for diabetes treatment.

Leggi questa versione → originale

valor.globo.com3 g fa

Em parceria com laboratório Adalvo, Sandoz ingressa no mercado de semaglutida com Owozy

Em parceria com laboratório Adalvo, Sandoz ingressa no mercado de semaglutida com Owozy

Leggi questa versione → originale

giovedì 30 luglio 2026·

thehindubusinessline.com

Sun Pharma gets green signal on semaglutide in Brazil, its second export market

Sun Pharma gains ANVISA approval to launch semaglutide in Brazil, partnering with Hypera Pharma for diabetes treatment.

giovedì 30 luglio 2026·

thehindu.com

Sun Pharma gets Brazil nod for Semaglutide

Sun Pharma receives ANVISA approval to launch semaglutide in Brazil, expanding diabetes treatment options in a $413 million market.

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com